

Letter of Support of the German Hemophilia Society for the World Federation of Hemophilia's Applications for the WHO Model Lists of Essential Medicines 2025 Update (C.1 Changes to listings of cryoprecipitate, pathogen-reduced cryoprecipitate, and plasma-derived clotting factor concentrates; A.23 Recombinant coagulations factors – haemophilia; A.12 Emicizumab – haemophilia A)

We are reaching out to you to support the three applications submitted by the World Federation of Hemophilia (WFH) as part of the 2025 update of the WHO Model Lists of Essential Medicines. As a patient organization for people with bleeding disorders, we are deeply concerned about the therapeutic safety of the global bleeding disorders community.

Technological advances have transformed treatment options for people with hemophilia. Today, prophylactic treatment to prevent bleeding is the standard of care for people with hemophilia globally, achieved through the administration of clotting factor concentrates (CFCs) and Factor VIII mimetic bispecific antibodies and TFPI-antibodies.

The WHO Model Lists of Essential Medicines serve as a vital tool guiding national governments in selecting and funding medicines. Therefore, we are gravely concerned about the inclusion of pathogen-reduced and non-pathogen-reduced cryoprecipitate as core medicines on the Model Lists of Essential Medicines in 2023, while virally safe, plasma-derived CFCs remain on the complementary medicines list. Using cryoprecipitate poses a significant risk of transmission of bloodborne infections, such as HIV and hepatitis B and C, for people with hemophilia, von Willebrand Disease, and other bleeding disorders. Moreover, it cannot be used for prophylactic treatment, and thus it does not prevent further health complications from bleeding.

The current Model Lists of Essential Medicines do not reflect the global standard of care and best clinical practices for managing people with hemophilia. Therefore, we call on the WHO to accept the WFH recommendations for revising the WHO EML in 2025.

We further urge the WHO to include clinicians with expertise in managing hemophilia and other bleeding disorders on the Twenty-Fifth WHO Expert Committee for the Selection and Use of Essential Medicines.

We ask you to consider the points mentioned above and hope that the 2025 updates will bring the EML in line with current international clinical practice guidelines and help reduce

the risks of bloodborne pathogen transmission and further complications from bleeding for people with hemophilia A and von Willebrand Disease.

Hamburg, 4th April 2025



Rainer Stähler
Vorsitzender des Vorstandes



Alf Kreienbring
Stv. Vorsitzender



Dr. Günter Auerswald
Stv. Vorsitzender